1
William J Kelleher, Anthony E Carpanzano: Sustained release drug-resin complexes. Richardson Vicks, David K Dabbiere, Douglas C Mohl, Jack D Schaeffer, February 26, 1991: US04996047 (105 worldwide citation)

Disclosed are oral pharmaceutical preparations which comprise a pharmacologically active drug bound to small particles of an ion-exchange resin to provide a drug-resin complex having a drug content above a specified value. The drug-resin complex is subsequently coated with a water-permeable diffusio ...


2
Curtis Wright IV, Anthony E Carpanzano: Oral dosage form comprising a therapeutic agent and an adverse-effect agent. Purdue Pharma, Duane Morris, June 10, 2008: US07384653 (32 worldwide citation)

The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is cove ...


3
Anand R Baichwal, Philip A Goliber, Anthony E Carpanzano, Thomas Sciascia, Donald Diehl II, Brian Vogler, David Verbel, Stanley Au: Sustained release formulations of nalbuphine. Penwest Pharmaceuticals Co, Davidson Davidson & Kappel, March 12, 2013: US08394812 (3 worldwide citation)

Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acce ...


4
Curtis Wright IV, Anthony E Carpanzano: Oral dosage form comprising a therapeutic agent and an adverse-effect agent. Purdue Pharma, Lowenstein Sandler, December 22, 2015: USRE045822

The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is cove ...


5
Anand R Baichwal, Philip A Goliber, Anthony E Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au: Sustained release formulation of nalbuphine. Endo Pharmaceuticals, Davidson Davidson & Kappel, January 8, 2019: US10172798

Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acce ...


6
Anand R Baichwal, Philip A Goliber, Anthony E Carpanzano, Thomas Sciascia, Donald Diehl II, Brian Vogler: Sustained release formulation of nalbuphine. Endo Pharmaceuticals, Davidson Davidson & Kappel, November 17, 2015: US09186330

Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acce ...


7
Anand R Baichwal, Philip A Goliber, Anthony E Carpanzano, Thomas Sciascia, Donald Diehl II, Brian Vogler, David Verbel, Stanley Au: Sustained release formulation of nalbuphine. ENDO PHARMACEUTICALS, Davidson Davidson & Kappel, May 31, 2016: US09351938

Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acce ...


8
Lino Tavares, Bruce E Reidenberg, Richard S Sackler, Curtis Wright, Mark A Alfonso, Benjamin Oshlack, James P Cassidy, Anthony E Carpanzano, Rampurna P Gullapalli, Ihor Shevchuk: Abuse resistant opioid containing transdermal systems. Darby & Darby PC, December 2, 2004: US20040241218-A1

The present invention relates to transdermal dosage form (FIG. 1-3) comprising at least one activating agent and at least one inactivating agent. The dosage form (FIG. 1-3) releases the inactivating agent upon disruption of the dosage form (FIG. 1-3) thereby preventing or hindering misuse of the act ...


9
Curtis Wright, Anthony E Carpanzano: Oral dosage form comprising a therapeutic agent and an adverse-effect agent. Euro Celtique, Jones Day, March 24, 2005: US20050063909-A1

The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is cove ...


10
Anand R Baichwal, Philip A Goliber, Anthony E Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler: Sustained release formulations of nalbuphine. Penwest Pharmaceuticals Co, Wilmer Cutler Pickering Hale And Dorr, March 1, 2007: US20070048376-A1

Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acce ...